COVID Unrest, Health Sector Deep Freeze Hits Chinese Biotechs Hard
Some Already Responding To Challenges
Executive Summary
Much of the biopharma and other health-related industries in China were already feeling the chill from ongoing macro-economic and other headwinds this year, which now look set to be complicated further by the added strain of social unrest over strict COVID containment policies. The combination of factors is already prompting some to take steps towards restructuring and divestments to survive.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.